<DOC>
	<DOCNO>NCT01995539</DOCNO>
	<brief_summary>The purpose India iPro2 study demonstrate iPro2 Continuous Glucose Monitoring System ( CGMS ) evaluation enable Health Care Professional ( HCP ) treat patient India type 2 diabetes get well understanding patient 's metabolic fluctuation , support appropriate therapeutic intervention .</brief_summary>
	<brief_title>Use iPro™2 Real Life Diabetes Management Type 2 Patients India</brief_title>
	<detailed_description>The study design demonstrate value iPro2 real-world diabetes management type 2 patient India . It interventional post-market , prospective , multi-center study data review perform 30 subject complete trial . During course study , patient undergo two iPro2 evaluation : - First iPro2 test ( Visit 1 [ application ] &amp; 2 [ removal ] ) - Second iPro2 test ( Visit 3 [ application ] &amp; 4 [ removal ] ) Patient HCP questionnaire administer Visit 1 , 2 , 3 , 4 5 . These questionnaire aim assess impact iPro2 evaluation physician understanding patient 's metabolic fluctuation support therapeutic intervention . They also investigate subject understand ( pre &amp; post iPro2 evaluation ) concept glycemic variability importance compliance HCP recommendation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : 1 . Subject &gt; 18 year ≤ 70 year age 2 . Subject diagnose type 2 diabetes mellitus least 1 year currently treat oral antihyperglycemic medication and/or insulin 3 . Subject 's A1C &gt; 8.0 % ≤ 10 % conduct last 4 week 4 . Subject , legal representative , sign study Patient Informed Consent Form ( PIC ) 5 . Subject willing comply study procedure Exclusion criterion : 1 . Subject unable tolerate tape adhesive area sensor placement 2 . Subject pregnant , expect become pregnant course trial per Investigator discretion . 3 . Subject experience SMBG blood glucose meter use 4 . Subject undergone iPro evaluation past 6 month 5 . Subject unresolved adverse skin condition area sensor placement ( e.g. , psoriasis , rash , Staphylococcus infection ) 6 . Subject actively participate plan actively participate investigational study ( drug device ) wherein he/she receive treatment investigational study drug investigational study device last 2 week 7 . Subject history visual impairment would allow subject participate study perform study procedure safely , determine investigator 8 . Subject unresolved alcohol drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Type 2</keyword>
</DOC>